Penn State Hershey Children's Hospital

Hershey, Pennsylvania 17110

2 studies enrolling now · 41 studies all time

What they study most

ALL, ALS, AML, Acute Leukemia of Ambiguous Lineage, Acute Respiratory Distress Syndrome, Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Studies at this site

• Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies — Recruiting now
• The Pediatric Anesthesia Quality Improvement Project — Recruiting now
• A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease — Completed
• Safety Study of Oral Edaravone Administered in Subjects With ALS — Completed
• Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) — Completed
• HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors — Running, not enrolling
• A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Completed
• Linking Endotypes and Outcomes in Pediatric Acute Respiratory Distress Syndrome — Completed
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma — Running, not enrolling
• Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years — Completed
• Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children — Completed
• Pediatric Obesity Weight Evaluation Registry (POWER) Study — Completed
• Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma — Stopped early
• Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia — Completed
• Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension — Completed
• Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia — Completed
• Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure — Completed
• MRI Markers of Outcome After Severe Pediatric TBI — Completed
• Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma — Completed
• Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma — Completed
• Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes — Completed
• Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma — Completed
• Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors — Completed
• Autism Spectrum Ambassador Program — Completed
• Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder — Completed
• Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia — Completed
• Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma — Completed
• Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission — Completed
• Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients — Stopped early
• Antibiotic Safety (SCAMP) — Completed
• POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients — Completed
• Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia — Completed
• Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma — Completed
• Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors — Completed
• Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma — Completed
• Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter — Stopped early
• Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma — Completed
• Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus — Stopped early
• Cue-based Tactile Stimulation and Infant Stress Reactivity — Completed
• Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma — Completed
• Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors — Completed